Comparison of Lipid Profile, Liver Enzymes, Creatine Kinase and Lactate Dehydrogenase Among Type II Diabetes Mellitus Patients on Statin Therapy

References

• Borle AL, Chhari N, Gupta G, Bathma V. Study of prevalence and pattern of dyslipidaemia in type 2 diabetes mellitus patients attending rural health training centre of medical college in Bhopal, Madhya Pradesh. Int J Community Med Public Health. 2017;3(1):140–144.
   Google Scholar
• Mistire WG. Diabetes mellitus and associated diseases from Ethiopian perspective: systematic review. Ethiop J Health Dev. 2013;27(3):249–253.
   Google Scholar
• Krikorian A. Standards of medical care in diabetics. J Am Diabet Assoc. 2016;39(Suppl. 1):S1–S2.
   Google Scholar
• Kawanami D, Matoba K, Utsunomiya K. Dyslipidemia in diabetic nephropathy. Ren Replace Ther. 2016;2:16. doi:10.1186/s41100-016-0028-0
   Google Scholar
• Wu L, Parhofer KG. Diabetic dyslipidemia. Metab Clin Exp. 2014;63:1469–1514. doi:10.1016/j.metabol.2014.08.010
   PubMed Web of Science ®Google Scholar
• Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5(3):150–159. doi:10.1038/ncpendmet1066
   PubMedGoogle Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058. doi:10.1093/eurheartj/ehw272
   PubMed Web of Science ®Google Scholar
• Basak RC, Chatterjee M, Sarma P. An overview on management of diabetic dyslipidemia. J Diabetes Endocrinol. 2013;4(3):27–36.
   Google Scholar
• Gencer B, Mach F. Review of the 2016 European dyslipidaemia guidelines. Cardiovasc Med. 2016;19(11):283–287.
   Google Scholar
• Rutishauser J. The role of statins in clinical medicine-LDL-cholesterol lowering and beyond. Swiss Med Wkly. 2006;136(3/4):41–49.
   PubMedGoogle Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–2561. doi:10.1016/S0140-6736(16)31357-5
   PubMed Web of Science ®Google Scholar
• Hennessy E, Adams C, Reen FJ, O’Gara F. Statins as next generation anti- microbials: is there potential for repurposing?. Antimicrob Agents Chemother. 2016;AAC–00192.
   Google Scholar
• Joo SJ. Anti-inflammatory effects of statins beyond cholesterol lowering. Korean Circ J. 2012;42(9):592–594. doi:10.4070/kcj.2012.42.9.592
   PubMedGoogle Scholar
• Bitztur R, Cohen H, Kamari Y, Harats D. Intolerance to statins: mechanisms and management. Diabetes Care. 2013;36(2):S325–S330. doi:10.2337/dcS13-2038
   PubMedGoogle Scholar
• Russo MW, Hoofnagle JH, Gu J, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology. 2014;60(1):679–686. doi:10.1002/hep.27157
   PubMedGoogle Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel statement on assessment, aetiology and management. Eur Heart J. 2015;36(17):1012–1022. doi:10.1093/eurheartj/ehv043
   PubMed Web of Science ®Google Scholar
• Maji D, Shaikh S, Solanki D, Gaurav K. Safety of statins. Lancet. 2013;17(4):636–646. doi:10.4103/2230-8210.113754
   Google Scholar
• Ambapkar S, Shetty N, Dwivedy A. Statin-Induced Rhabdomyolysis. J Associ Physi India. 2016;64:93–94.
   PubMedGoogle Scholar
• Pedro-Botet J, Millán Núñez-Cortés J, Chillarón JJ, Flores-le Roux JA, Rius J. Severity of statin-induced adverse effects on muscle and associated conditions: data from the DAMA study. Expert Opin Drug Saf. 2016;15(12):1583–1587. doi:10.1080/14740338.2016.1238068
   PubMed Web of Science ®Google Scholar
• Tokinaga K, Oeda T, Suzuki Y, Matsushima Y. HMG-CoA Reductase Inhibitors (statins) might cause high elevation of creatine phosphokinase (CPK) in patients with unnoticed hypothyroidism. Endo J. 2006;53(3):401–405. doi:10.1507/endocrj.K04-144
   PubMedGoogle Scholar
• Moghadam-kia S, Oddis CV, Aggarwal R. Approach to asymptomatic creatine kinase elevation. Cleve Clin J Med. 2016;83(1):37–42. doi:10.3949/ccjm.83a.14120
   PubMed Web of Science ®Google Scholar
• Faloppi L, Bianconi M, Memeo R, et al. Lactate dehydrogenase in hepatocellular carcinoma: something old, something new. Biomed Res Int. 2016;2016. doi:10.1155/2016/7196280
   PubMedGoogle Scholar
• Miao P, Sheng S, Sun X, Liu J, Huang G. Lactate dehydrogenase A in cancer: a promising target for diagnosis and therapy. IUBMB Life. 2013;65(11):904–910. doi:10.1002/iub.1216
   PubMed Web of Science ®Google Scholar
• Imai K, Watari S, Sakazume T, Mitsuyama S. Clinical chemistry and immunoassay testing supporting the individual healthy life. Hitachi Rev. 2008;57:1–7.
   Google Scholar
• Balgi V, Harshavardan L, Sahna E, Thomas SK. Pattern of lipid profile abnormality in subjects with prediabetes. Int J Sci Study. 2017;4(11):150–153.
   Google Scholar
• Trentman TL, Avey SG, Ramakrishna H. Current and emerging treatments for hypercholesterolemia: a focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians. J Anaesthesiol Clin Pharmacol. 2016;32:4405. doi:10.4103/0970-9185.194773
   Google Scholar
• Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering—are they clinically relevant? Eur Heart J. 2003;24(3):225–248. doi:10.1016/S0195-668X(02)00419-0
   PubMed Web of Science ®Google Scholar
• Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5(4):378–387. doi:10.1111/jcmm.2001.5.issue-4
   PubMed Web of Science ®Google Scholar
• Takata K, Psaltis PJ, Nicholls SJ. Investigate the long term legacy of statin therapy. J Thorac Dis. 2017;9(4):936–939. doi:10.21037/jtd.2017.03.10
   PubMedGoogle Scholar
• Ford I, Murray H, McCowan C, Packard CJ. Long term safety and efficacy of lowering LDL cholesterol with statin therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention study. Circulation. 2016;115:1073–1080.
   Google Scholar
• Lu Y, Cheng Z, Zhao Y, et al. Efficacy and safety of long term treatment with statin for coronary heart disease: a Bayesian network meta-analysis. Atherosclerosis. 2016;254:215–227. doi:10.1016/j.atherosclerosis.2016.10.025
   PubMed Web of Science ®Google Scholar
• Han H, He Y, Hu J, Lau R, Lee H, Ji C. Disrupted ER-to-golgi trafficking underlies anti-HIV drugs and alcohol-induced cellular stress and hepatic injury. Hepatol Commun. 2017;1(2):122–139. doi:10.1002/hep4.1030
   PubMedGoogle Scholar
• Kullak-Ublick GA, Andrade RJ, Merz M, et al. Drug induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017;2016:1154–1164.
   Google Scholar
• Marrone G, Vaccaro FG, Biolato M, et al. Drug-induced liver injury: the diagnosis is not easy but always to keep in mind. Eur Rev Med Pharmacol Sci. 2017;21(1 Suppl):122–134.
   PubMedGoogle Scholar
• Dragos D, Pruteanu D, Constantin R. High-dose statin associated with rhabdomyolysis, acute kidney injury, cholestatic liver injury, and thrombocytopenia. J Nephrol Kidney Dis. 2017;1(1):1001. doi:10.36876/smjnkd
   Google Scholar
• Thapar M, Russo MW, Bonkovsky HL. Statins and liver injury. Gastroenterol Hepatol (N Y). 2013;9(9):605.
   PubMedGoogle Scholar
• Gao Y, Wang Y, Wu NQ, et al. Statins use and the risk of liver dysfunction: a Chinese cohort study in real world clinical practice. IJC Metab Endocr. 2017;16:16–20. doi:10.1016/j.ijcme.2017.06.003
   Google Scholar
• Björnsson ES. Hepatotoxicity by drugs: the most common implicated agents. Int J Mol Sci. 2016;17(2):224. doi:10.3390/ijms17020224
   PubMed Web of Science ®Google Scholar
• Clarke AT, Johnson PC, Hall GC, Ford I, Mills PR. High dose atorvastatin associated with increased risk of significant hepatotoxicity in comparison to simvastatin in UK GPRD cohort. PLoS One. 2016;11(3):e0151587. doi:10.1371/journal.pone.0151587
   PubMed Web of Science ®Google Scholar
• Ortega-Alonso A, Stephens C, Lucena MI, Andrade RJ. Case characterization, clinical features and risk factors in drug-induced liver injury. Int J Mol Sci. 2016;17(5):714. doi:10.3390/ijms17050714
   PubMed Web of Science ®Google Scholar
• Egholm G, Pareek M.Drug-induced rhabdomyolysis with elevated cardiac troponin T. Case Rep Med.2015;2015:1–3. doi:10.1155/2015/270204
   Google Scholar
• Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127:96–103. doi:10.1161/CIRCULATIONAHA.112.136101
   PubMed Web of Science ®Google Scholar
• Soko N, Dandara C, Ramesar R, Kadzirange G, Masimirembwa C. Pharmacokinetics of rosuvastatin in 30 healthy Zimbabwean individuals of African ancestry. Br J Clin Pharmacol. 2016;82:326–328. doi:10.1111/bcp.12915
   PubMedGoogle Scholar
• Calza L, Magistrelli E, Colangeli V, et al. Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patients. AIDS. 2017;31:681–688. doi:10.1097/QAD.0000000000001397
   PubMed Web of Science ®Google Scholar
• Holder K. Myalgias and myopathies: drug-induced myalgias and myopathies. FP Essent. 2016;440:23–27.
   PubMedGoogle Scholar
• Auer J, Sinzinger H, Franklin B, Berent R. Muscle- and skeletal-related side- effects of statins: tip of the iceberg? Eur J Prev Cardiol. 2016;23(1):88–110. doi:10.1177/2047487314550804
   PubMedGoogle Scholar
• Mohammed NB, Elias SE. Assessment of gamma glutamyl transferase and lactate dehydrogenase as biochemical markers of preeclampsia severity in sudanese pregnant women’sin Khartoum State. Savant J Med Sci. 2016;2(9):177–183.
   Google Scholar
• Noor M, Waheed A, Muhammad I, Bakhtiar S. Is co q10 really valuable in shielding statin induced myopathy-an exploration? Pakistan Armed Forces Med J. 2016;66(4):525–529.
   Google Scholar
• Unnikrishnan D, Satish B. Exertion induced rhabdomyolysis in patients on statin therapy. Nephrol Dial Transplant. 2005;20(1):24. doi:10.1093/ndt/gfh578
   Google Scholar